Main Industry
Biotechnology
Main Product/Service
Acepodia’s core offering is allogeneic cell‑therapy for cancer — using targeted design and cell‑engineering technologies to develop safe and effective therapeutic cell drugs, aiming to provide patients with a next‑generation, broadly applicable cancer tre
The content above was translated by Ai
Founded Year
2023
Unified Business No.
82983710
Status
Active
Number of Employees
60
Total Paid-in
Capital
- (NT$)
Exit Status
Emerging Stock Exchange(2023)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acepodia Inc., a member (No. 64) of the Taiwan Research‑based Biopharmaceutical Manufacturers Association (TRPMA), is a biotech startup focused on developing novel allogeneic cell therapies for cancer, aiming to advance new possibilities in oncology treatment.
The content above was translated by Ai
